Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Cutaneous Lupus Erythematosus
NCT06980805Phase 2Active, not recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of IMVT-1402 in cutaneous lupus erythematosus (CLE), sponsored by Immunovant, Inc.. Started Feb 2025; status: active, not recruiting.
02
Drugs
IMVT-1402
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT06980805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980805.